



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2022 #40

November 11, 2022

INSIDE:

RESEARCH IN BRIEF	3
ABC Webinar: Blood Product Inventory Management-Strategies for Donor Center & Hospital Partnerships ...	4
October <i>Blood Bulletin</i> Published.....	4
Input Requested: 2023 ABC Advocacy Agenda	4
WORD IN WASHINGTON	5
PEOPLE.....	5
MEMBER NEWS.....	6
GLOBAL NEWS	7
COMPANY NEWS	7
CALENDAR.....	8
EQUIPMENT AVAILABLE	9
POSITIONS.....	9

ABC Launches Career Recruitment Video

America's Blood Centers (ABC) has developed a new "[Career in Blood](#)" recruitment video to assist member blood centers in attracting a diverse pool of jobseekers in the face of workplace shortages impacting industries across the country. This member-exclusive resource is available in both English and Spanish with male and female narration and can be used on websites and social media channels.

"The blood community is not immune from the workforce issues confronting industries nationwide right now. We're proud to release this new resource to help our members recruit and retain a diverse pool of jobseekers at a critical time," said Kate Fry, MBA, CAE chief executive officer at America's Blood Centers. "A position at a blood center is more than a job — it is an opportunity to make a lifesaving difference in your community."

Whether jobseekers are hoping to transfer their existing skills or are looking for an entry level position with on-the-job training, an opportunity is available at a community blood center. The video highlights how the blood center team includes phlebotomists, communications and marketing staff, laboratory professionals, and more, all focused on a single mission: the lifesaving power of blood donation.

ABC is continuing to work on a shorter 30-second version of this video that will be available soon. In addition, ABC is seeking ideas for similar videos that would assist blood centers in their hiring. Please contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#) with questions or concepts that would help you attract and retain staff.

(Source: ABC [News Release](#), 11/8/22) ♦

Lab-grown RBCs Transfused

Researchers in the United Kingdom have [grown](#) red blood cells in a laboratory that have now been transfused to an individual in "a world first clinical trial." According to a news release from NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the United Kingdom, "The manufactured blood cells were grown from stem cells from donors. The red cells were then transfused into volunteers in the RESTORE randomi[z]ed controlled clinical trial...If proved safe and effective, manufactured blood cells could in time revolutioni[z]e treatments for people with blood disorders such as sickle cell and rare blood types. It can be difficult to find enough well-matched donated blood for some people with these disorders."

(continued on page 2)



Lab-grown RBCs Transfused (continued from page 1)

The clinical trial is a collaboration between NHSBT and the University of Bristol, working with the University of Cambridge, Guy's and St Thomas' NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Cambridge Clinical Research Facility, and Cambridge University Hospitals NHS Foundation Trust. According to the announcement, "Two people have so far been transfused with the lab grown red cells. They were closely monitored, and no untoward side effects were reported. They are well and healthy. The identities of participants infused so far are not currently being released, to help keep the trial 'blinded.' The amount of lab grown cells being infused varies but is around 5-10mls - about one to two teaspoons. Donors were recruited from NHSBT's blood donor base. They donated blood to the trial and stem cells were separated out from their blood. These stem cells were then grown to produce red blood cells in a laboratory at NHSBT's Advanced Therapies Unit in Bristol. The recipients of the blood were recruited from healthy members of the NIHR BioResource. A minimum of 10 participants will receive two mini transfusions at least four months apart, one of standard donated red cells and one of lab grown red cells, to find out if the young red blood cells made in the laboratory last longer than cells made in the body. Further trials are needed before clinical use, but this research marks a significant step in using lab grown red blood cells to improve treatment for patients with rare blood types or people with complex transfusion needs... The trial is studying the lifespan of the lab grown cells compared with infusions of standard red blood cells from the same donor. The lab-grown blood cells are all fresh, so the trial team expect them to perform better than a similar transfusion of standard donated red cells, which contains cells of varying ages."

(Source: NHSBT [News Release](#), 11/7/22) ♦



The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Rita Reik
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to
memberservices@americasblood.org
 America's Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.



RESEARCH IN BRIEF

Are Aged Platelets a Risk Factor for TRALI? A [study](#) in *Transfusion* “investigated the effect of platelet concentrate (PC) storage time on pathways leading to the development of transfusion-related acute lung injury (TRALI) in a two-hit *in vivo* human autologous platelet transfusion model...Eighteen healthy male volunteers were allocated to transfusion of fresh (2-day-old) PC, aged (7-day-old) PC, or infusion of normal saline...Activation markers CD62P and CD63 and apoptosis marker phosphatidylserine were measured.” The authors explained that “[t]he experiment started with the bolus of 2 ng/kg Escherichia coli lipopolysaccharide (LPS) as first hit...Two hours after, volunteers received either fresh or aged PC or saline as [the] second hit.” The study found that “aged products expressed significantly more activation markers...The percentage of CD62P positive platelets was 5.0 ± 4.8 in the fresh platelets group and 11.0 ± 3.2 in the aged platelets group, $p = .03$...The percentage of CD63-positive platelets was 1.1 ± 0.8 in the fresh platelets group and 3.2 ± 1.1 in the aged platelets group, $p = .004$...There was no difference in the percentage of phosphatidylserine-positive platelets, $p = .8$...All subjects reacted to the LPS infusion: temperature increased from $36.6 \pm 0.5^\circ\text{C}$ at baseline to $38.7 \pm 0.8^\circ\text{C}$, pulse increased from $68/\text{min} \pm 14$ to $105/\text{min} \pm 9$, and oxygen saturation decreased from 100 ± 0.6 to 98 ± 1.3 percent.” The authors noted that “[b]lood neutrophil count increased until the end of the experiment, from $2.8 \times 10^9/\text{L} \pm 1.0$ at baseline to $13.9 \times 10^9/\text{L} \pm 3.4$ and then returned to normal levels.” “There were no significant between-group differences in bronchoalveolar lavage fluid (BALF) protein content ($95 \pm 33 \mu\text{g}/\text{ml}$, $83 \pm 21 \mu\text{g}/\text{ml}$, and $104 \pm 29 \mu\text{g}/\text{ml}$, respectively for the saline, fresh, and aged PC group)...When comparing pre-transfusion and post-transfusion values for respiratory parameters, there were no between-group differences...None of the subjects met TRALI criteria.” The authors concluded that “autologous transfusion of longer stored platelets in the presence of endotoxemia does not increase pulmonary fluid and neutrophil leakage nor decrease respiratory function in a human experimental model of mild TRALI, suggesting that increased storage duration alone does not increase TRALI risk.”

Citation: van Baarle, F.L.F., de Bruin, S., Bulle, E.B., van Mourik, N., Lim, E.H.T., Tuip-de Boer, A.M., et al. [Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury](#). *Transfusion*. 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

Upcoming ABC and ADRP Webinars – Don’t Miss Out!

- **ABC Blood Product Inventory Management: Donor Center & Hospital Transfusion Service Perspectives** – November 15 from 3-4:30 PM EST. More information including the link to join the webinar available to ABC members in MCN 22-094. Contact [us](#) for a copy of the MCN.
- **ABC Scientific, Medical, and Technical Journal Club Webinar** – December 7 from 3-4 PM EST. More information coming soon!

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



America's Blood Centers
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ABC Webinar: Blood Product Inventory Management-Strategies for Donor Center & Hospital Partnerships

ABC will host a webinar titled “Blood Product Inventory Management-Strategies for Donor Center & Hospital Partnerships” on November 15th at 3 p.m. EST. Attendees will hear speakers “share their expertise in blood product inventory management to include handling product shortages, ordering, and communication strategies. This webinar will include both presentations and roundtable discussions. ABC encourages members to invite their hospital customers to participate in the webinar to share their insights. Speakers include:

- Wayne Bottner, MD, Medical Director, Blood Bank, Hematologist, Gundersen Healthcare, La Crosse, WI
- Afton Tarasewicz, MLT(ASCP), Lead Tech-Blood Bank, Gundersen Healthcare, La Crosse, WI
- Lindsay Peters, MLS (ASCP) SBBcm, Director, Customer Relations at ImpactLife
- Angela Treml, MD, Medical Director, Transfusion Medicine, Versiti
- Marc Lewis, LSSYB, VP of Operations – Business Development, Production Management & Regional Operations, Gulf Coast Regional Blood Center.

P.A.C.E credits will be offered. A link to join the webinar and additional information is available to ABC members in MCN 22-094. Contact [us](#) to receive a copy of the MCN.

(Source: MCN 22-094, 11/7/22)

October Blood Bulletin Published

America's Blood Center's (ABC) has published the October 2022 edition of the redesigned [Blood Bulletin](#). This issue is titled: “Cryoprecipitate (Cryo) and Alternatives” and [PDF](#) or [MS Word](#) versions are available. The article was written by Courtney Hopkins, DO, Senior Chief Medical Officer at Vitalant, Samantha Ngamsuntikul, MD, Associate Medical Director at South Texas Blood & Tissue Center, a subsidiary of BioBridge Global, Richard Gammon, MD, Medical Director at OneBlood, Ruchika Goel, MD, MPH, Medical Director at ImpactLife, Nancy Van Buren, MD, Medical Director at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center. Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife was also a contributor. [Blood Bulletin](#) is reviewed and edited by ABC's Scientific, Medical, and Technical (SMT) Publications Committee.

(Source: MCN 22-092, 10/25/22)

Input Requested: 2023 ABC Advocacy Agenda

ABC, in consultation with the ABC Board of Directors and the ABC Policy Council, is currently developing its 2023 Advocacy Agenda. The input and feedback from member blood centers is important to this process. A link to a brief survey is available to all ABC members in MCN 22-093 (contact [us](#) to receive a copy of the MCN). Please provide your feedback by Friday, November 18th. The ABC Advocacy Agenda reflects

(continued on page 5)



INSIDE ABC (continued from page 4)

the federal legislative and regulatory issues most important to blood centers. The 2023 Advocacy Agenda will build upon the work completed over the past year. ABC thanks the many volunteers and partners who helped advance the policy issues outlined in the [2022 Advocacy Agenda](#). Please contact ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#) with questions or comments.

(Source: MCN 22-093, 10/26/22) ♦

WORD IN WASHINGTON

The Office of the Assistant Secretary for Health (OASH), within the U.S. Department of Health and Human Services (HHS), submission for a red blood cell antibody repository has been chosen for development as part of the HHS Secretary’s “Challenge on Equity.” The project is expected to be implemented in the next two years and is one of 24 innovative projects selected to advance equity in programs, policies, and processes across the agency.

(Source: OASH Announcement, 11/2/22)

The FDA [published](#) a guidance on November 1st titled “Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) — Small Entity Compliance Guide.” The guidance “supersedes the small entity compliance guide of the same title” issued August 2007. According to the agency, “the small entity compliance guide is intended to help small entity establishments that manufacture HCT/Ps better understand the comprehensive regulatory framework for HCT/Ps set forth in the regulations and comply with certain HCT/P-related final rules.”

(Source: FDA [Guidance](#), 11/1/22)

HHS Secretary Xavier Becerra, JD [extended](#) the monkeypox virus Public Health Emergency (PHE) effective November 2nd, 2022. The PHE has been in effect since August 4th and was renewed for another 90 days due to the “continued consequences of an outbreak of monkeypox cases across multiple states.” The U.S. Food and Drug Administration (FDA) has previously [stated](#) that “[w]orldwide, there have been no reports of transmission of monkeypox virus through blood transfusion and the risk of transfusion-transmission remains theoretical. The levels of virus in the blood of an infected or exposed individual have not been well characterized.”

(Source: HHS [Announcement](#), 11/2/22) ♦

PEOPLE



Becky Cap, MBA has been [named](#) senior vice president of Business Development for BioBridge Global Advanced Therapies as the organization expands its services into advanced therapies. “This is a natural extension of our organization and mission,” said BioBridge Global Chief Executive Officer Martin Landon in a news release. “Our customers pursuing cell and gene therapy breakthroughs have needs that extend beyond just process development and biomanufacturing, and we have capabilities across our enterprise to support and aid those efforts. Becky is perfectly positioned to coordinate these cross-enterprise activities and services, and we’ve developed a solid portfolio of offerings and capabilities in this space.” Ms. Cap previously served as the chief operating officer of GenCure, a wholly owned biomanufacturing subsidiary of BioBridge Global. In her new role, she will “take on responsibilities from strategy to business development to relationship management in the

(continued on page 6)

PEOPLE (continued from page 5)

advanced therapies space,” according to a news release. Ms. Cap earned “a bachelor’s degree from Harvard University and an MBA from Boston University’s Questrom School of Management. She began her career at Dana-Farber Cancer Institute in Boston. Her move to industry began at Eidetics, a consulting firm focused on informing biomedical product development strategy and execution. She is an active member of local and national committees on regenerative medicine and cell therapy and serves on two private company boards of directors.”

(Source: BioBridge Global [News Release](#), 11/2/22)



Kevin Gramlich, RN assumed the role of chief executive officer (CEO) of ConnectLife on November 1st. According to the ConnectLife announcement, he will “oversee and manage all operations of the multi-million-dollar non-profit and will be responsible for establishing a structure that meets the needs of ConnectLife and its goals. Mark Simon will continue as the President of ConnectLife and the organization’s top executive, focusing on long-term goals and mission-driven results.” Mr. Simon added in a news release, “Kevin’s experience and dedication to our mission make him the perfect successor as CEO of ConnectLife. I have proudly served this organization for over 25 years and

look forward to working side by side with Kevin as he leads ConnectLife with integrity, compassion, accountability, and respect.” Mr. Gramlich “has been a part of ConnectLife (formerly Unyts) for more than 25 years. He first served as a clinical donation coordinator working in our local hospitals with donor families and has worked in several other management roles, including senior vice president of Clinical Services and chief operations officer, prior to his appointment as CEO. In his 20+ years at ConnectLife Mr. Gramlich has been integral in the organization’s growth as one of the most successful Organ Procurement Organizations in the country. He is actively involved in the transplant and donation industry across the U.S., participating on many boards and committees including- North American Transplant Coordinators Organization, New York State Transplant Council, Donate Life New York State Legislative Committee, New York Center for Liver Transplantation Consortium, New York Cardiothoracic Transplant Consortium, New York State Transplant and OPO Covid-19 Committee, Kidney Foundation of WNY, and the WNY Covid Vaccination Hub Task Force.”

(Source: ConnectLife [News Release](#), 9/27/22) 💧

MEMBER NEWS



Carter BloodCare recently celebrated the [opening](#) of its 26th donor center with a ribbon-cutting ceremony in McKinney, Texas, north of Dallas. In attendance with the Carter BloodCare team were McKinney Mayor George Fuller, McKinney City Council Member Patrick Cloutier, representatives of the McKinney Chamber of Commerce, and several McKinney business leaders from the chamber’s Ambassador Program. Along with Carter BloodCare’s ongoing mobile blood drives across North Texas, the McKinney Donor Center provides Collin County residents with a convenient donation location to help others. The new center accepts whole blood, double red cell, plasma, and platelet donations.

(Source: Carter BloodCare [Announcement](#), 10/13/22)

Contributed by James Black, Public Relations Specialist at Carter BloodCare 💧



GLOBAL NEWS

NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the United Kingdom (UK), is [partnering](#) with Marvel Studios to encourage blood donation, particularly among individuals of Black Caribbean and Black African heritage. The [promotion](#) coincides with the release of Marvel Studios' most recent film, Black Panther: Wakanda Forever. According to NHSBT, the collaboration is the "next stage in the organization's 'Not Family, But Blood' campaign to recruit more Black blood donors, urgently needed to meet increasing demand to treat conditions such as sickle cell... This is NHSBT's third blood donation film partnership with Disney and its second with Marvel Studios following collaborations with Free Guy in 2021 and Doctor Strange In the Multiverse of Madness earlier this year. It is hoped the collaboration with Marvel Studios will boost the campaign by reaching more people of Black heritage, particularly younger film fans who may not have considered blood donation... The 'Not Family, But Blood' NHS campaign highlights that although the Black community is diverse, one unifying thing is the power to provide life changing blood donations. This thought is amplified in the people of Wakanda – different tribes, but together they are stronger, supporting and protecting their community. Co-branded Black Panther: Wakanda Forever digital content will be shared across NHSBT, Disney, and Marvel Studios social channels with a call to action for people to register as a blood donor. An exclusive pre-movie screening will be held at Hackney Picturehouse in London for specially invited NHSBT supporters including patients, donors, and partners alongside representatives from Black local businesses."

(Source: NHSBT [Announcement](#), 11/2/22)

FIFA World Cup™ volunteers recently [teamed](#) up with Hamad Medical Corporation (HMC), the main provider of specialist healthcare services for Qatar, to host a blood drive ahead of the FIFA World Cup™, which gets underway in Qatar later this month. According to an announcement from FIFA, "[v]olunteers arriv[ed] for their final training sessions ahead of the FIFA World Cup Qatar 2022™ [and] were greeted by one of HMC's Mobile Blood Donation Units just outside the Doha Exhibition Cent[er] and soon began lining up by the dozens to answer the call and donate blood."

(Source: FIFA World Cup™ [Announcement](#), 11/9/22) 💧

COMPANY NEWS

Cerus Corp. has been [awarded](#) a federal contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program. According to a company news release, the \$9.1 million contract is for the "development of pathogen reduced, lyophilized cryoprecipitate ("LyoCryo") to treat bleeding due to trauma. [LyoCryo] is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic injury bleeding... The "Golden Hour" is the critical time a bleeding patient must be resuscitated with blood transfusion to enhance survival, yet conventional blood products are not feasible for use in far-forward austere combat environments or at the point of injury. With this project and the associated funding, Cerus and DoD will collaborate to bring a product to patients that addresses a critical unmet need for early treatment of traumatic bleeding." Cerus also stated in the news release that "[the company] has been working to develop a lyophilized, pathogen reduced cryoprecipitate product and has advanced this program through several important development milestones, including product feasibility... [T]he associated funding will support the scale-up of manufacturing technology for the LyoCryo product and developing preliminary data to support a U.S. Food and Drug Administration (FDA) submission for regulatory review."

(Source: Cerus Corp. [News Release](#), 11/2/22)

(continued on page 8)

COMPANY NEWS (continued from page 7)

Emergent BioSolutions Inc. recently shared [data](#) from a phase II trial of its adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in prior recipients of other investigational alphavirus vaccines. The trial aimed to “evaluat[e] the safety and immunogenicity” of the vaccine candidate “in comparison to a cohort of alphavirus vaccine-naïve individuals.” The reported data showed that the “vaccine candidate was well-tolerated with no notable difference in the incidence of adverse events between the groups. The majority of solicited adverse events were mild or moderate. The most common adverse event was local injection site pain. The seroconversion rate 21 days post-vaccination was 100 percent in both groups. A higher percentage of prior alphavirus vaccine candidate recipients had a four-fold rise on study day eight than the alphavirus vaccine-naïve group.”

(Source: Emergent BioSolutions Inc. [News Release](#), 11/1/22)

The **Association for the Advancement of Blood & Biotherapies (AABB)** [announced](#) that its National Blood Foundation has “relaunched” as the AABB Foundation. According to the organization, the “new name and branding underscore the expanding reach and growing importance of the Foundation’s work and better align the Foundation to the mission of AABB...[T]he AABB Foundation will continue the important work of funding early-stage investigators, while also expanding the ways in which it supports innovative research and education for the field.”

(Source: AABB [Announcement](#), 11/2/22) ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2022

Nov. 15. **ABC Blood Product Inventory Management: Donor Center & Hospital Transfusion Service Perspectives Webinar.** Login link and additional information are available to ABC members in MCN 22-094. Contact [us](#) for a copy of the MCN.

Nov. 15-16. **The Biomedical Advanced Research and Development Authority (BARDA) Industry Day (Virtual).** More details available [here](#).

Nov. 17. **U.S. Department of Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) Meeting (Virtual).** More details available [here](#).

Dec. 7. **ABC Scientific, Medical, and Technical Journal Club Webinar.** More information coming soon.

Dec. 8. **U.S. Food and Drug Administration Blood Products Advisory Committee Meeting (Virtual).** More details available [here](#).

(continued on page 9)

POSITIONS (continued from page 8)

2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** Hotel and additional information are available [here](#).

April. 24-28. **ABC Blood Center Advocacy Week.** More information coming soon.

Sept. 21-22. **29th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** Call for abstracts, hotel information, and more are available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧

EQUIPMENT AVAILABLE

For Sale. 2023 All American Blue Bird Bus: 6.7L Diesel Engine with 6 Speed Allison Transmission/Air Breaks/Air Suspension/Wheelbase: 232"/100 Gallon Fuel Tank. This bus is ready for you to convert into your blood mobile Price: \$155k. ****IMMEDIATE POSSESSION**** **location: ROCKFORD, IL** Please contact Gary at (815) 961-2307 or gperry@rvbc.org.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Laboratory Tech I or II -- 2nd shift (Rhode Island Blood Center). This position is responsible for the execution of testing and quality control (QC) procedures following Standard Operating Procedures, as assigned. Testing includes routine donor testing in large batches, as well as component qualifications. This position is responsible for proper disposition of components based on test or QC results. This position also works with the Supervisor of Client Testing to ensure appropriate test menus are completed as ordered and reported. Essential Functions: High complexity testing of donor blood samples with proper technique and documentation according to the procedures of the Rhode Island Blood Center, including computer and physical quarantine. Carrying out all procedures in a reasonable time frame as determined by supervisory personnel. Labeling of blood components including proper checking and documentation according to the procedures of the Rhode Island Blood Center Laboratory. This position is a Second Shift position. Five 8-hour shifts or Four 10-hour shifts. Qualifications: MLT, BB, MT or equivalent, or SBB (ASCP) certification. Must meet requirements for Testing Personnel for a Highly Complex Laboratory as described in the Clinical Laboratory Improvement Act of 1988. Data entry skills preferred. Click [here](#) to view the full job description and apply.

Medical & Laboratory Director – South Division. Vitalant is currently seeking a Medical & Laboratory Director to provide oversight for the patients, donors, staff, and healthcare professionals in our South Division (TN, LA, MS, NM, TX). Routine duties include blood center activities such as component manufacturing, product management, laboratory testing, donor suitability and counseling, education, & consultation and clinical services activities such as oversight of an immunohematology reference laboratory, transfusion services, therapeutic apheresis, and cellular therapy collections (e.g., Dendreon). Additional areas of specialization, such as cell sourcing and cellular therapy/cord blood, may be assigned as needed. This position works directly with the Corporate and Division teams to promote Vitalant's mission, vision, quality policy, and strategic initiatives to position Vitalant as a Center of Transfusion Medicine Excellence. Modeling high ethical, customer care, and confidentiality standards always, this person serves a vital role for assuring compliance with current policies, programs, and directives and providing medical support for the Blood Services Division and Vitalant Clinical Services. This role can work remotely anywhere within the South Division (TN, LA, MS, NM,

(continued on page 10)

POSITIONS (continued from page 9)

TX) with 20 percent travel to visit internal and external partners but preference is given to candidates located in either LA or TN. How to apply: <https://bloodsystems.taleo.net/careersection/jobdetail.ftl?job=222681&lang=en>

Donor Services Operations Director (Oklahoma Blood Institute - Enid, Oklahoma). To provide leadership and direction over all aspects of mobile operation activities. To ensure that processes are in place to reach optimal department efficiency by meeting successful product collection, financial, quality, compliance, and customer service goals. All tasks undertaken, regardless of their timing, that have clear applicability to blood banking and transfusion medicine are considered within this position's scope of employment and are, therefore, subject to the Institute's Intellectual Property Policy and Procedures. Qualifications: Bachelor's degree in management or medical field preferred, minimum of five years' leadership/management experience, blood bank focus preferred and valid driver's license. Salary: Competitive salary based on education and/or experience and **\$500 bonus after 6 months and \$1,000 bonus after 1 year!** **Benefits:** Health, dental, vision, life insurance, long term disability, 401(k), paid-time off, \$5,000 annual tuition reimbursement, holiday pay, etc. How to apply: <http://obi.org/careers/>

Divisional Director. The Blood Connection is seeking a Divisional Director to provide oversight to our day-to-day operations in Charlotte, NC. This position provides direction for the division and ensures that directed departments meet divisional objectives. The Divisional Director will help provide support to executive management for the evaluation, planning, and execution of expansion into new territories. The ideal candidate will be a self-starter with a minimum of five years of progressive management experience. Candidates must possess excellent interpersonal, analytical, and strategic planning abilities. We offer an exceptional benefits package including a generous 401k match, 30 days PTO, company bonuses, tuition reimbursement, cell phone stipend, and yearly increases. Join one of the fastest growing blood centers in the country and help make an impact in your community today! How to apply: [Divisional Director Application](#)

Executive Director of Arkansas Blood Institute (Little Rock, Arkansas). The Arkansas Blood Institute is seeking a "community spirited" professional to **LEAD its Little Rock team** in fulfilling the mission to recruit blood donors, drive sponsors, and volunteers and to store and deliver blood units for local hospitals. This public-facing, "visible" position not only requires an outgoing, bright, and energetic personality to foster relationships, but also demands detailed attention to planning, communication,

regulations, finances, and personnel. Significant successes in project management and organizational expansion and entrepreneurship are desirable. Connectivity with regional leaders and access to key social networks would also be positives. The successful candidate will present and maintain a credible, positive image of the Arkansas Blood Institute in the local community. He/She will act as a liaison between the Institute and the community, organizations, and residents. Applicants should be goal-driven self-starters who have strong interpersonal, organizational, and analytic skills. They should be able to motivate and inspire diverse constituencies including donors, sponsors, staff, and volunteers. Salary Range: Competitive salary, commission plan, and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, tuition reimbursement, referral bonus, and retention bonus. How to apply: <http://arkbi.org/careers/>

Sr. Director, Biotherapies Quality. Vitalant is currently seeking a Sr. Director of Biotherapies Quality to provide support and leadership in advancing performance related to compliance, process improvement, and risk mitigation in the area of Biotherapies, including, but not limited to cellular therapy collections and processing, collection of starting materials for biotherapy treatments, apheresis therapeutic procedures and clinical laboratories such as HLA and Specialty Coag labs. This role will be located in our corporate headquarters in Scottsdale, AZ and lead a geographically dispersed team who comprise the quality staff overseeing these activities. This Sr. Director is a highly visible leader and an integral member of the Quality Leadership team who assures quality in their areas of oversight. How to apply: <https://bloodsystems.taleo.net/careersection/jobdetail.ftl?job=222962&lang=en>

Technical Director. Central California Blood Center based in Fresno, seeks ideal candidate for the position of Technical Director. Specialist in Blood Banking (SBB ASCP) preferred, at least 10 years blood donor testing and component manufacturing experience required, including leadership position(s). California CLS license strongly preferred. Seeking a proven leadership-skilled individual who builds teams, collaborates, mentors, and innovates. The Technical Director is responsible for our blood donor testing laboratory, blood components manufacturing, phase III clinical trial research and biomanufacturing, immunohematology reference lab, and providing technical guidance to donor services when needed. Current area of responsibility includes over 25 FTE. Responsible for designing programs and tactics in line with company strategic goals, participating in senior leadership, assuring all processes and SOP are in compliance with state and federal regulations and AABB. Collaborates with Medical Director and other senior leaders to assure compliance, effectiveness, and positive

(continued on page 11)



POSITIONS (continued from page 10)

culture within the company. Excellent salary and benefits package. How to apply: <https://www.donateblood.org/career-opportunities/>. 💧